ALMKT:EPA
Mauna Kea Technologies SA
€0,092
0,00%
(0,00) 1D
13 ພ.ຈ., 17 ໂມງ 35 ນາທີ 01 ວິນາທີ GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0,09
High
€0,10
Low
€0,09
Mkt. cap
18,14 ລ້ານ
Avg. vol.
541,14 ພັນ
Volume
75,16 ພັນ
P/E ratio
0,79
52-wk high
€0,23
52-wk low
€0,07
EPS
€0,12
Shares outstanding
195,26 ລ້ານ
No. of employees
56
Open
€0,09
High
€0,10
Low
€0,09
Mkt. cap
18,14 ລ້ານ
Avg. vol.
541,14 ພັນ
Volume
75,16 ພັນ
P/E ratio
0,79
52-wk high
€0,23
52-wk low
€0,07
EPS
€0,12
Shares outstanding
195,26 ລ້ານ
No. of employees
56
News stories
From web sources and news partners
Crypto Briefing
·
48 ນາທີກ່ອນ
Anthropic targets $1.4T valuation in NASDAQ IPO, eyes AI market impact
The Globe and Mail
·
29 ນາທີກ່ອນ
Tesla Is Down 13% in 2026 While the S&P 500 Is Up. Here’s the 1 Catalyst Left This Year That Could Flip That.
TheStreet
·
2 ຊົ່ວໂມງກ່ອນ
Goldman Sachs reset S&P 500 price target for 2027
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA
CEOSacha Loiseau
Employees56
Founded2000
Headquarters-
SectorHealth Care
IndustryMedical device
Websitemaunakeatech.com